肾细胞癌下腔静脉结扎不重建与取栓术的结局比较:回顾性病例对照研究
这项单中心回顾性病例对照研究将26例肾细胞癌行下腔静脉结扎不重建的患者与52例行下腔静脉取栓术的患者按1:2匹配,比较并发症、肾功能变化和死亡率。结扎组90天再入院率和术后并发症率更高,但1个月后持续并发症率、18个月时估算肾小球滤过率下降程度及肿瘤特异性和全因死亡率均无显著差异。结论认为两种术式长期结局相似。
要点
- 下腔静脉结扎不重建与取栓术的长期肾功能恢复、并发症率和生存相似。
- 结扎组术后早期并发症率和90天再入院率更高,需加强围手术期管理。
- 术前肾功能、肿瘤分期和癌栓分级匹配后,两种术式肿瘤学结局无显著差异。
核心结论
- 肾细胞癌下腔静脉结扎不重建与取栓术的长期结局相似,但结扎组早期术后病程更复杂。
研究设计与样本
- 单中心高容量机构回顾性病例对照研究,2005至2019年26例下腔静脉结扎不重建患者按1:2匹配52例下腔静脉取栓术患者,匹配因素为术前肾功能、肾细胞癌分期和术中癌栓水平。
主要发现
- 结扎组90天再入院率为19%,取栓组为4%(p=0.025)。
- 结扎组术后并发症率为73%,取栓组为39%(p=0.004);淋巴水肿发生率分别为23%和8%(p=0.055)。
- 1个月随访时持续总体并发症率分别为49%和31%(p=0.497),持续主要并发症率均为8%(p=1.000)。
- 18个月随访时平均估算肾小球滤过率下降在结扎组为8.5 ml/min/1.73 m2,取栓组为9.9 ml/min/1.73 m2(p=0.834)。
- 肿瘤特异性死亡率(p=0.993)和全因死亡率(p=0.756)差异无统计学意义。
临床怎么用
- 对于肿瘤癌栓侵犯下腔静脉壁需行下腔静脉结扎不重建的患者,应预期更高的早期并发症和再入院风险并加强术后管理。
- 结扎不重建可作为取栓术的替代选择,长期肾功能和生存结局相似。
局限性
- 回顾性单中心研究,样本量较小(结扎组26例),可能存在选择偏倚和混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radical nephrectomy with tumor thrombectomy is considered standard of care in patients with renal cell carcinoma. However, surgical ligation and interruption of the inferior vena cava is sometimes necessary when the tumor thrombus invades the inferior vena cava wall. This study assesses the outcomes in patients with renal cell carcinoma undergoing inferior vena cava ligation compared to inferior vena cava thrombectomy. MATERIALS AND METHODS: We conducted a case controlled, retrospective study at a high volume single-center institution. All patients with renal cell carcinoma who underwent ligation without reconstruction were matched with patients undergoing thrombectomy in a 1:2 ratio based on preoperative renal function, renal cell carcinoma stage and intraoperative thrombus level. Endpoints were complications, change in renal function and mortality. RESULTS: A total of 26 patients with renal cell carcinoma who underwent inferior vena cava ligation between 2005 and 2019 were matched with 52 patients who underwent inferior vena cava thrombectomy in the same time period. When compared to thrombectomy, patients undergoing ligation had higher 90-day readmission rate (19% vs 4%, p=0.025). The ligation group also had a higher postoperative complication rate (73% vs 39%, p=0.004) and higher rates of lymphedema (23% vs 8%, p=0.055). However, by 1-month followup the rate of persistent overall and major complications for both ligation and thrombectomy groups were comparable at 49% vs 31% (p=0.497) ad 8% vs 8% (p=1.000), respectively. Importantly, at 18-month followup, mean estimated glomerular filtration rate declines were similar between ligation group (8.5 ml/min/1.73 m2) and thrombectomy group (9.9 ml/min/1.73 m2; p=0.834). Differences in cancer-specific mortality (p=0.993) and all-cause mortality (p=0.756) were also not statistically significant. CONCLUSIONS: The outcomes of inferior vena cava ligation compared to inferior vena cava thrombectomy for renal cell carcinoma are similar. Patients with inferior vena cava ligation initially face a more complicated postoperative course but in the longer term have similar renal function recovery, complication rates and survival.
引用
- Xie L, Hong G, Nabavizadeh R, et al. Outcomes in Patients with Renal Cell Carcinoma Undergoing Inferior Vena Cava Ligation without Reconstruction versus Thrombectomy: A Retrospective, Case Controlled Study. J Urol. 2020. PMID: 32903154. doi:10.1097/JU.0000000000001354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。